| Serial Number | 79211373 |
| Word Mark | ANEMOCYTE |
| Filing Date | Monday, February 6, 2017 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, April 10, 2018 |
| Registration Number | 5440621 |
| Registration Date | Tuesday, April 10, 2018 |
| Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, January 23, 2018 |
| Description of Mark | The mark consists of the following: the stylized term "ANEMOCYTE" with the letters "ANEM" and "YTE" appearing in dark grey, and the letters "OC" merged and appearing in light blue, green, blue and light grey. |
| Goods and Services | Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human and veterinary medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy |
| Indication of Colors claimed | The color(s) light blue, green, blue, light grey and dark grey is/are claimed as a feature of the mark. |
| Goods and Services | Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 8, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 8, 2017 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | ANEMOCYTE S.R.L. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IT |
| Party Name | ANEMOCYTE S.R.L. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IT |
| Party Name | ARETA INTERNATIONAL S.R.L. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | IT |
| Event Date | Event Description |
| Tuesday, April 9, 2024 | TEAS SECTION 71 & 15 RECEIVED |
| Monday, April 10, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Monday, October 24, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, October 24, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, October 24, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Monday, October 24, 2022 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Monday, October 24, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, October 24, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, October 24, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, April 9, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Saturday, August 11, 2018 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Monday, July 16, 2018 | FINAL DISPOSITION NOTICE SENT TO IB |
| Monday, July 16, 2018 | FINAL DISPOSITION PROCESSED |
| Tuesday, July 10, 2018 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, April 10, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, February 22, 2018 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Saturday, February 10, 2018 | NOTIFICATION PROCESSED BY IB |
| Tuesday, January 23, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, January 23, 2018 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 3, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, January 3, 2018 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, January 3, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, December 11, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, December 11, 2017 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, December 11, 2017 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 11, 2017 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, October 20, 2017 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, October 20, 2017 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, August 4, 2017 | REFUSAL PROCESSED BY IB |
| Tuesday, July 18, 2017 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, July 18, 2017 | REFUSAL PROCESSED BY MPU |
| Wednesday, July 12, 2017 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, July 12, 2017 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, July 11, 2017 | NON-FINAL ACTION WRITTEN |
| Saturday, July 8, 2017 | ASSIGNED TO EXAMINER |
| Saturday, July 8, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, July 7, 2017 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Thursday, July 6, 2017 | SN ASSIGNED FOR SECT 66A APPL FROM IB |